Emerging treatments
Eravacycline
Eravacycline is a novel antibiotic of the tetracycline class. One clinical trial indicated that it is at least as effective as ertapenem in treating complicated intra-abdominal infections (cIAIs).[138] Eravacycline may have a role in the treatment of complicated appendicitis. The Food and Drug Administration (FDA) and the European Medicines Agency have approved eravacycline for the treatment of complicated intra-abdominal infections (cIAIs) in adults.
Meropenem/vaborbactam
Meropenem/vaborbactam is a carbapenem beta-lactamase inhibitor combination that has demonstrated higher clinical cure rates, versus best available therapy, for the treatment of carbapenem-resistant Enterobacteriaceae, among other infections.[139] The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended granting authorization for meropenem/vaborbactam for the treatment of several types of infection, including cIAIs. Meropenem/vaborbactam is approved by the FDA for the treatment of complicated urinary tract infections in adults.
Imipenem/cilastatin/relebactam
Imipenem/cilastatin/relebactam is a three-drug combination containing imipenem-cilastatin, a previously FDA-approved antibiotic, and relebactam, a new beta-lactamase inhibitor. The FDA has approved this combination to treat adults with complicated urinary tract infections and cIAIs.
Use of this content is subject to our disclaimer